Antelope
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
Compared with
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
Cumulative number of new active lesions
MRI lesions
Other measures (1)
- new active lesions over time
MRI lesions
Who could take part
Relapsing MS
Inclusion: - Male and female patients (age ≥18 to 60 years), with RRMS. Exclusion: - Manifestation of multiple sclerosis (MS) other than RRMS.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Evaluate and compare the cumulative number of new active lesions
Papers
Loading reviews and guidelines…
Related trials
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…
Recruiting
Still running
- A Study Utilising Data From European Union (EU) National …
Running, not recruiting
Still running
- SATURATE-MS
Stopped early
Stopped early
- A Study to Investigate the Radiological Onset of Action A…
Phase 4 · Stopped early
Stopped early
- The 'Wearing Off' Effect of DMT
Completed
No result found
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, a…
Phase 3 · Stopped early
Stopped: not working
History
Started
Apr 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error